Drugs / Pritumumab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04396717 | Feb 2021 → Jan 2023 | metastatic malignant neoplasm in the brain | Nascent Biotech | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 14
| Date | Issuer | Release |
|---|---|---|
| 2025-02-11 | Nascent Biotech | Regulatory Message From Senior Management nascentbiotech.com ↗
Its response was favorable, allowing us to begin Phase II studies. |
| 2023-08-22 | Nascent Biotech | Regulatory Nascent Biotech to Begin Phase II Clinical Trials for Brain Cancer nascentbiotech.com ↗ |
| 2023-06-06 | Nascent Biotech | Results Journal of Clinical Oncology: Phase 1 study of pritumumab in brain cancer. nascentbiotech.com ↗
15 patients received the investigational agent and were evaluable for safety and efficacy analyses. |
| 2023-05-01 | Nascent Biotech | Regulatory A Letter to Nascent Biotech Shareholders, May 1, 2023 nascentbiotech.com ↗
We have submitted the clinical plan to the FDA and are anticipating clearance to begin soon. |
| 2023-04-18 | Nascent Biotech | Regulatory Nascent Submits Phase 2 Clinical Research Protocol to FDA for Review and Approval nascentbiotech.com ↗
Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage biotechnology Company whose business is focused in the brain cancer space, announced today that the Protocol for the Phase 2 clinical trials was submitted to the FDA for review and approval. |
| 2022-11-01 | Nascent Biotech | Regulatory Nascent Biotech Receives Notice of the Issuance of US Patent No.11,494,394 nascentbiotech.com ↗ |
| 2022-07-19 | Nascent Biotech | Regulatory Nascent Biotech Receives Notice of Allowance from USPTO for Issuance of Additional Patent nascentbiotech.com ↗ |
| 2021-02-17 | Nascent Biotech | Results Nascent Biotech Announces Successful Pritumumab In-Vitro Trial Data in Collaborative Covid-19 Treatment Study with Syracuse University nascentbiotech.com ↗
The data show that Pritumumab (“PTB”) successfully blocked 80% of viral entry into cells. |
| 2020-12-15 | Nascent Biotech | Regulatory Nascent Biotech Receives Full IND Clearance to Begin Phase I Human Trials for Brain Cancer nascentbiotech.com ↗
On December 7, the Company received a letter from the US Food and Drug Administration (FDA) removing a partial clinical hold on Nascent’s proprietary monoclonal antibody Pritumumab. |
| 2020-10-20 | Nascent Biotech | Results Nascent Biotech Announces Promising Covid-19 Invitro Study Results with Syracuse University Collaboration nascentbiotech.com ↗ |
| 2018-12-11 | Nascent Biotech | Regulatory Nascent Biotech Receives Clearance from FDA to Begin Phase I Human Trials in Brain Cancer nascentbiotech.com ↗
Nascent Biotech, Inc. (OTC: NBIO) Received US Food and Drug Administration (FDA) Clearance to begin Phase 1 Clinical Trials effective December 7th, 2018. |
| 2016-04-25 | Nascent Biotech | Regulatory Nascent Biotech Announces Orphan Drug Designation for Pancreatic Cancer nascentbiotech.com ↗
Nascent Biotech, Inc., (OTC.NBIO) is pleased to announce that it has been granted Orphan Drug Designation from the Office of Orphan Products Development of the FDA for its Pritumumab product for the treatment of Pancreatic cancer. |
| 2015-08-13 | Nascent Biotech | Regulatory Nascent Biotech Achieves Two Key Milestones in Development of its Novel Brain Cancer Treatment nascentbiotech.com ↗
Another significant milestone worth noting is that the FDA granted Nascent Biotech an Orphan Drug Designation for Gliomas (brain cancer). |
| 2015-04-09 | Nascent Biotech | Regulatory Nascent Biotech Announces Orphan Drug Designation for Brain Cancer nascentbiotech.com ↗ |
All press releases naming this drug 23 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pritumumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04396717 ↗ |
| Known as | ACA-11 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108045 ↗ |
| Known as | CLN-IGG | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108045 ↗ |
| Known as | CLNH-11 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108045 ↗ |
| Modality | Monoclonal antibody | “Pritumumab IgG1 human monoclonal antibody” NCT04396717 ↗ |
| Route | Intravenous | “Pritumumab administered sequentially as 1-hour IV infusion” NCT04396717 ↗ |
| Target | VIM | “Vimentin other” CHEMBL2108045 ↗ |